Researchers identify potential new drug target for treating Barth syndrome

"We found that lyso-cardiolipin, an intermediate accumulating in mutant TAZ-deficient cells, interacts with the mitochondrial protein cytochrome c, converting it to a demon enzyme that oxidizes everything around it," said Valerian Kagan, professor of environmental and occupational health.